Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Sema4 Holdings — Investor Presentation (February 2022)
25 slides from Genedx's investor presentation, Feb 22, 2022
Slide 1: Investor Presentation
sema4 Investor Presentation February 2022
Slide 2: Disclaimer
Disclaimer
Slide 3: A Patient-Centered Health Intelligence Company Leveraging Genomics and AI
A Patient-Centered Health Intelligence Company Leveraging Genomics and Al
Slide 4: Corporate Snapshot
Corporate Snapshot World-class team 2022 guidance ——_‘Unrivaled patient access Massive scale indata Massive scale in NGS 1,200+ employees $215-225MSema4 12M de-identified records 46+ petabytes 250,000+2 ED eDSTakBED standalone revenue? 500k+ w/ genomic profiles managed growing at an tests annually 3
Slide 5: Sema4 & GeneDx Combination Drives Growth & Profitability
Sema4 & GeneDx Combination Drives Growth & Profitability Standalone Revenue Pro Forma Long-Term Growth (Historical and Estimated, $ millions) (ex-COVID, $ millions) 2021E 2022E 2023E = 2024E_- = 2028E Revenue Growth? #20% «= #21% += -#36% «= -+34% «428% Adjusted Gross Margin 5% 16% 33% 43% 50% 20208
Slide 6: The Problem
The Problem Diagnoses Rapid advances in Genomics & Al... .-but limited impact on patients sema4
Slide 7: Our Solution: A Holistic Approach to Patient Care
Our Solution: A Holistic Approach to Patient Care... —$_!_—_—_~ ECS, NIPT, Hereditary Cancer, Use of multiple methods and and Natalis solutions designed technologies, each with with flexibility to meet ‘accuracy of >99% patient needs euneeice Flexible, science and eee methodologies alll Sema4 Reprod
Slide 8: Combined with Centrellis, our Flywheel for Patient Data and Insights
..Combined with Centrellis, our Flywheel for Patient Data and Insights Enhanced Data Feed Channels Insights & Engagement Health Systems Clinical Trials EMR, Imaging, Molecular, Claims Clinical Decision Support Third Parties Population Health Models EMR, Imaging, Molecular, Claims Patients & Provider
Slide 9: Deep Partnership with Health Systems
Deep Partnership with Health Systems (Accelerating clinical exome with GeneDx) nal aenomics Model eno men Enabling Precision Medicine sold direct to as the Standard of Care sema4
Slide 10: Evolution Towards a Platform of Algorithms
Evolution Towards a Platform of Algorithms 4 wicreasea auto MONETIZE INFORMATION Patients, Providers, PLATFORM TO QUERY 7 Pharma FOR INSIGHTS Matching patients to products and services (moving beyond providers and life science) SECONDARY INSIGHTS Novel disease mod that inform clini are and trial red
Slide 11: The Value of Data: Must be Longitudinal and Prescriptive
The Value of Data: Must be Longitudinal and Prescriptive Psd cones MULTLDISEASE Colected over time = Gide seees toot ENRICHED EE «/0r0nc0" LoucrTuoNaL # LLL ren ee oxnparon Curated clinical notes = a 0 2"? 8 ey z / & 45 SOPH a Loncrupinal & a © 50 =" Coledtedovertins EE v:i21 \— es © EPISODIC | Pont
Slide 12: NorthShore: The First Six Months
NorthShore: The First Six Months Over 90% of primary care physicians at NorthShore have ordered from Sema4 Genetic Wellness and Assessment Program 42,000 Patient group v 6,400 Had genomic health screen test ordered Completed NCCN guid Heritable Cancer Screening Mammography Pilot compliance to prescr
Slide 13: Enabling Biopharma Partners and Customers
Enabling Biopharma Partners and Customers SEMA4 OFFERING Deep Partnerships leveraging data science Clinical trial matching SaaS-based licensing [— LEAD IDENTIFICATION EARLY CLINICAL ——) ;~ PROTOCOL OPTIMIZATION REAL WORLD DATA Drive increased probability of Reduce trial duration, Maximize trial oppo
Slide 14: Enhancing Our Reach into Health Systems & Biopharma
Enhancing Our Reach into Health Systems & Biopharma Molecular Profiling and Real-World Evidence Merus sema4 Pabento Recer + SANOFI Drug Discovery Collaboration _ yanssen J Clinical Trial Match and Recruitment into Trials wiHealth System Partners Health System Dominant Partnership HS-Pharm Synergisti
Slide 15: A Market-Leading AI-Driven Genomic & Clinical Data Platform
A Market-Leading Al-Driven Genomic & Clinical Data Platform Generating Data/ Growing Patient Base = GeneDx: 145K te: with 180K+ patient sema4 Increasing Scale = Semaé4: 12M patients with de-identified records & + managing 46+ petabytes of data = GeneDx: Adding 2.1M expert-curated phenotypes Genek =
Slide 16: Increases Longitudinal Engagement and Enhances Centrellis
Increases Longitudinal Engagement and Enhances Centre anding From Patient Engagement into Family Health ($50B+ TAI Women’s NICU & | Newborn Genomic Health Health: $4B Outpatient: $38 [| Screening: $10B Screening: $16B Oncology: $18B it Reimbursement expanding Substantial cost savings | | —_ Increasi
Slide 17: 4Q Update: Strong Close to 2021!
4Q Update: Strong Close to 2021! 4Q Resulted Volume 4Q Total Revenue Expects total revenues the range of $50-52 million Guidance was $46.6 - 49.6 million? 7" Ourestimates of our fourth complete the prepara 240 guidance implied for 21 revenue, resulted volume and our cash and cash equivalents as of D
Slide 18: Operational Improvements: Key Highlights and Future Focus
Operational Improvements: Key Highlights and Future Focus Lab Operations Key Actions = Hired seasoned SVP Lab Operations = Key investments in Lab Automation Areas of Focus in 2022 = Improve turn-around-times = Portfolio optimization 18 t Commercial “> y Reach Act es Key Actions « Increased salesforc
Slide 19: Creating the Leading Genomic Data Platform, from Generation to Insights
Creating the Leading Genomic Data Platform, from Generation to Insights +} Serving Patients Throughout Life, Deeply Integrated Within Health Systems e Driving Growth and Scale in Genomic Diagnostics sema4 -E 3} Complementary Revenue Streams and Margin Optimization Opportunity Genek Strengthening Mar
Slide 20: Slide 20
Slide 21: Slide 21
Slide 22: Historical COVID Revenue Mix
Historical COVID Revenue Mix % of Total Revenue! 2Q20 3Q20 FY20 1Q21 2921 Diagnostic Test 99% 93% 84% 79% 73% 87% 86% COVID 0% 6% 14% 18% 25% 8% 10% Other 1% 1% 2% 2% 2% 4% 4% 22 =——
Slide 23: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation USD Millions #2020 Fy2021 10 2a 3a Fy 10 2a 3a Revenue 46.7 30.1 386 179.3 6aa 469 43.2 Cost of Service 393 36.0 365 184.6 ns 497 588 Gross (Loss) Profit 14 (5.9 2a (5.3 4) 2.8) 35.6) Gross Margin 15.8% (29.6%) 5.4% (3.0%) (11.5%) (6.0%) (36.1%) Stock-based compe
Slide 24: Non-GAAP EBITDA Reconciliation
Non-GAAP EBITDA Reconciliation USD Millions eer al 3a 2a 3a Fv 1a 2a 3a Net Profit (Loss) (27.0) (21) (56.6) (241.3) (191.0) (45.4) 314 Interest expense, net ” 02 05 06 20 07 07 07 Depreciation and amortization 24 27 3a 117 49 56 55 ‘Stock-based compensation expense 08 (0.2) 294 120.2 165.0 (0) 18.0
Slide 25: Sema4 Nasdaq Listed
SMFR Semadt Nasdaq Listed
Sema4 Holdings — Investor Presentation (February 2022) on 6ix